Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 20, 2026, ABUS trades at $4.36 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ABUS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ABUS recently traded at $4.36. Market cap is $823.73M. P/E ratio is 5.20. Revenue is $191.44M.
| Metric | Value |
|---|---|
| Price | $4.36 |
| Market Cap | $823.73M |
| P/E Ratio | 5.20 |
| EPS | $0.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.10 |
| 52-Week Low | $2.71 |
| Volume | 2.19M |
| Avg Volume | 0 |
| Revenue (TTM) | $191.44M |
| Net Income | $160.72M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.08M | $-33.50M | $-0.17 |
| 2024 | $6.17M | $-69.92M | $-0.38 |
| 2023 | $18.14M | $-72.85M | $-0.44 |
| 2022 | $39.02M | $-69.46M | $-0.46 |
ABUS analyst coverage data. Average price target: $0.00.